Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study
Authors' conclusion
Dexamethasone treatment did not significantly improve survival or time to clinical improvement in patients with diabetes and COVID-19 infection. Further prospective studies are needed to confirm these findings and determine potential mechanisms.
Study context
- Population
- Patients with diabetes hospitalised for COVID-19, 5 hospitals in the Johns Hopkins Health System, March 3, 2020–June 25, 2022529 per group analysed after matching
- Participants
- 2,361 patients
- Exposure
- Dexamethasone vs no dexamethasone
- Dexamethasonen = 529
- Controlsn = 529reference
- Outcome
- Time to death
- Follow-up
- Within 28 days
Methodological detailspropensity-score matched, multicentre (5 hospitals), Cox proportional hazards regression
- Propensity-score matched
- Multicentre (5 hospitals)
- Cox proportional hazards regression
Main finding
As reported in the abstract
Survival · 0- to 6-day and 7- to 28-day periods
- Survival rates did not differ significantly between dexamethasone and controls
- Matched cohort
Observational data: associations, not effects.
Secondary outcomes
Time to clinical improvement · 28 days
- Time to clinical improvement did not differ significantly
Safety
- No difference in incidence of DKA or HHS between the groups
Original publication
Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study. J Clin Endocrinol Metab. Published 17 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →